Severity
Low
FDA Drug recall · Reported March 25, 2020
Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets 750 mg.
Strides Pharma Science Limited recalled Potassium Chloride Extended-Release Tablets USP, 10mEq (750mg), 1000-count bottle, Rx on… - a low-severity action.
Potassium Chloride Extended-Release Tablets USP, 10mEq (750mg), 1000-count bottle, Rx on… was recalled by Strides Pharma Science Limited in March 25, 2020. Reason: Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets …. Check the official notice for the remedy. Verify recall #D-1029-2020 with the FDA Drug before acting.
The recall
Strides Pharma Science Limited issued this low-severity FDA Drug recall-Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets ….
Sourced from official FDA Drug enforcement records. Verify recall #D-1029-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1029-2020) was formally reported on March 25, 2020, with the manufacturer initiating the action on February 17, 2020. It is classified under Low severity (Class III), with a current status of Terminated. Strides Pharma Science Limited is listed as the recalling firm, operating out of Bangalore. Federal records list the affected scope as 2576 bottles.
The documented reason for this recall is: Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets 750 mg. Distribution data in the federal record shows the product reached: U.S.A. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
2576 bottles
Related Recalls
6
5 from same agency
Potassium Chloride Extended-Release Tablets USP, 10mEq (750mg), 1000-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bengaluru - 562106, India, Distributed by: Strides Pharma Inc., East Brunswick, NJ 08816, NDC 64380-861-08
Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets 750 mg.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1029-2020 |
| Date reported | March 25, 2020 |
| Date initiated | February 17, 2020 |
| Recalling firm | Strides Pharma Science Limited |
| Firm location | Bangalore |
| Affected scope | 2576 bottles |
| Distribution | U.S.A. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 25, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.